以静脉注射替奈普酶治疗视网膜中央和分支动脉阻塞的病例系列：替奈普酶治疗视网膜动脉阻塞。
A case series on treatment of central and branch retinal artery occlusion with intravenous tenecteplase: Tenecteplase for retinal artery occlusions.
机构信息
Kaiser Permanente Los Angeles, Department of Neurology 1505 N Edgemont St, Floor 5 Los Angeles, CA 90027, United States.
Comprehensive Stroke Program, OhioHealth Riverside Methodist Hospital, Columbus, OH, United States.
出版信息
J Stroke Cerebrovasc Dis. 2024 Jan;33(1):107488. doi: 10.1016/j.jstrokecerebrovasdis.2023.107488. Epub 2023 Nov 18.
OBJECTIVES
Central and branch retinal artery occlusions are disabling ischemic strokes of the retina for which established acute treatments are lacking. This is the first published report of the use of intravenous tenecteplase (TNK) for retinal artery occlusion, in which we describe the clinical course of four patients with central retinal artery occlusion (CRAO) and one patient with branch retinal artery occlusion (BRAO).
MATERIALS AND METHODS
Patients were retrospectively recruited to the study from two stroke centers. Clinical course was determined from review of electronic medical records. The primary outcomes of interest were short and long term complications as well as visual acuity at presentation and at any subsequent follow up.
RESULTS
There were no hemorrhagic complications. None of the four patients with CRAO experienced functional visual recovery (defined as improvement to 20/100 or better). The patient with BRAO had functional visual recovery.
CONCLUSIONS
Intravenous TNK may be a safe and reasonable treatment for CRAO and BRAO.
目的
中央和分支视网膜动脉阻塞是视网膜的一种致残性缺血性中风，目前缺乏有效的急性治疗方法。这是首次发表的使用替奈普酶（TNK）治疗视网膜动脉阻塞的报告，我们在此描述了 4 例中央视网膜动脉阻塞（CRAO）和 1 例分支视网膜动脉阻塞（BRAO）患者的临床过程。
材料和方法
从两个卒中中心回顾性招募患者入组本研究。通过电子病历回顾确定临床病程。主要观察终点为短期和长期并发症，以及就诊时和任何后续随访时的视力。
结果
无出血性并发症。4 例 CRAO 患者中均未出现功能视力恢复（定义为提高至 20/100 或更好）。1 例 BRAO 患者出现功能视力恢复。
结论
静脉注射 TNK 可能是治疗 CRAO 和 BRAO 的一种安全且合理的方法。
Zotero 插件